Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP

Open access

Published version of a preprint

Abstract

We aimed to develop an efficient, flexible and scalable approach to diagnostic genome-wide sequence analysis of genetically heterogeneous clinical presentations. Here we present G2P ( www.ebi.ac.uk/gene2phenotype ) as an online system to establish, curate and distribute datasets for diagnostic variant filtering via association of allelic requirement and mutational consequence at a defined locus with phenotypic terms, confidence level and evidence links. An extension to Ensembl Variant Effect Predictor (VEP), VEP-G2P was used to filter both disease-associated and control whole exome sequence (WES) with Developmental Disorders G2P (G2P DD ; 2044 entries). VEP-G2P DD shows a sensitivity/precision of 97.3%/33% for de novo and 81.6%/22.7% for inherited pathogenic genotypes respectively. Many of the missing genotypes are likely false-positive pathogenic assignments. The expected number and discriminative features of background genotypes are defined using control WES. Using only human genetic data VEP-G2P performs well compared to other freely-available diagnostic systems and future phenotypic matching capabilities should further enhance performance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-10016-3

Cites

Statistics

Figures

Fig. 1 Summary of LGMDET structure and application in diagnostic filtering. a summarizes the components of a LGMDET thread. Each locus-genotype-mechanism-disease-evidence thread (LGMDET) associates an allelic requirement and a mutational consequence at a defined locus with a disease entity and a confidence level and evidence links. The publicly available G2PDD and G2PCancer data can be searched or downloaded on the website (https://www.ebi.ac.uk/gene2phenotype). b gives examples for LGMDE threads from curated datasets. In addition to the publicly available G2PDD and G2PCancer data, G2PEye is actively curated and will be publicly available soon. Access to the curation system can be requested for the creation of user-defined datasets. c summarizes the workflow for diagnostic filtering. The VCF files derived from the next-generation sequence data are passed to VEP which uses Ensembl annotation data to compute and annotate the consequence of each variant. The VEP-G2P plugin runs as an additional step of the VEP analysis. It uses the results of VEP’s computations and annotations together with the knowledge from the LGMDETs to filter the variants from the patients input VCF file. The plugin results, plausible genotypes of likely deleterious variants, are returned together with the VEP output file for clinical review. d lastly, the combined analysis of running VEP and VEP-G2P is repeated for a control cohort. The comparison between results from a population unselected for disease with the results from a disease cohort yields the expected background to quantify diagnostic noise and to identify discriminating features between the two cohorts
Fig. 1 Summary of LGMDET structure and application in diagnostic filtering. a summarizes the components of a LGMDET thread. Each locus-genotype-mechanism-disease-evidence thread (LGMDET) associates an allelic requirement and a mutational consequence at a defined locus with a disease entity and a confidence level and evidence links. The publicly available G2PDD and G2PCancer data can be searched or downloaded on the website (https://www.ebi.ac.uk/gene2phenotype). b gives examples for LGMDE threads from curated datasets. In addition to the publicly available G2PDD and G2PCancer data, G2PEye is actively curated and will be publicly available soon. Access to the curation system can be requested for the creation of user-defined datasets. c summarizes the workflow for diagnostic filtering. The VCF files derived from the next-generation sequence data are passed to VEP which uses Ensembl annotation data to compute and annotate the consequence of each variant. The VEP-G2P plugin runs as an additional step of the VEP analysis. It uses the results of VEP’s computations and annotations together with the knowledge from the LGMDETs to filter the variants from the patients input VCF file. The plugin results, plausible genotypes of likely deleterious variants, are returned together with the VEP output file for clinical review. d lastly, the combined analysis of running VEP and VEP-G2P is repeated for a control cohort. The comparison between results from a population unselected for disease with the results from a disease cohort yields the expected background to quantify diagnostic noise and to identify discriminating features between the two cohortsCC BY · PubMed Central
Fig. 2 Diagnostically discriminative VEP-G2P disease-specific output. VEP-G2P analysis of three independent WES cohorts; DDD (n = 7357), CRC (n = 517) and GS (n = 315). a Odds ratios for samples carrying at least one valid G2P variant (passing the G2P criteria and on a canonical transcript) in 454 unique G2PDD monoallelic genes: DDD vs GS (red) and CRC vs GS (black); two-tail Fisher’s Exact Test: *p-value ≤ 5 × 10-2, **p-value ≤ 5 × 10-3, ***p-value ≤ 5 × 10-6, n.s not significant; considering only missense variants where SIFT and PolyPhen agree deleterious/damaging. b Odds ratios for samples carrying at least one valid G2P variant in 950 different G2PDD biallelic genes. No stop_lost and inframe_insertion variants were found in the GS cohort and few in DDD or CRC (p-value > 5 × 10−2). Error bars = 95% confidence intervals (CI) in a and b. c Proportion of individuals in the three cohorts (y-axis) carrying a particular number of LOF and missense (regardless of their SIFT/PolyPhen status and CADD score) variants reported by VEP-G2PDD (x-axis). The proportion of DDD individuals for which no VEP-G2PDD hit is found is significantly lower compared to CRC and GS cohorts, both for monoallelic (p-values for two-tail Fisher’s Exact Test comparing number of individuals for which no variants is found to those for which at least one variant is found: DDD vs GS = 7.9e-09, DDD vs CRC = 2.3e-12, CRC vs GS = 0.93) and biallelic genes (DDD vs GS = 1.5e-10, DDD vs CRC = 1.5e-11, CRC vs GS = 0.39). DDD (n = 7357 individuals), CRC (n = 517), GS (n = 315). d DDD cohort is significantly enriched for unique missense variants with CADD > 30 in G2PDD genes (top) compared to GS (p-value two-tail Fisher’s Exact Test = 0.005); with no significant difference between DDD and CRC (p-value = 0.17) and CRC and GS (p-value = 0.16). There is no significant difference for the proportion of unique missense variants with CADD > 30 in the CRC and GS cohorts in G2PCancer genes (bottom, p-value = 1.0)
Fig. 2 Diagnostically discriminative VEP-G2P disease-specific output. VEP-G2P analysis of three independent WES cohorts; DDD (n = 7357), CRC (n = 517) and GS (n = 315). a Odds ratios for samples carrying at least one valid G2P variant (passing the G2P criteria and on a canonical transcript) in 454 unique G2PDD monoallelic genes: DDD vs GS (red) and CRC vs GS (black); two-tail Fisher’s Exact Test: *p-value ≤ 5 × 10-2, **p-value ≤ 5 × 10-3, ***p-value ≤ 5 × 10-6, n.s not significant; considering only missense variants where SIFT and PolyPhen agree deleterious/damaging. b Odds ratios for samples carrying at least one valid G2P variant in 950 different G2PDD biallelic genes. No stop_lost and inframe_insertion variants were found in the GS cohort and few in DDD or CRC (p-value > 5 × 10−2). Error bars = 95% confidence intervals (CI) in a and b. c Proportion of individuals in the three cohorts (y-axis) carrying a particular number of LOF and missense (regardless of their SIFT/PolyPhen status and CADD score) variants reported by VEP-G2PDD (x-axis). The proportion of DDD individuals for which no VEP-G2PDD hit is found is significantly lower compared to CRC and GS cohorts, both for monoallelic (p-values for two-tail Fisher’s Exact Test comparing number of individuals for which no variants is found to those for which at least one variant is found: DDD vs GS = 7.9e-09, DDD vs CRC = 2.3e-12, CRC vs GS = 0.93) and biallelic genes (DDD vs GS = 1.5e-10, DDD vs CRC = 1.5e-11, CRC vs GS = 0.39). DDD (n = 7357 individuals), CRC (n = 517), GS (n = 315). d DDD cohort is significantly enriched for unique missense variants with CADD > 30 in G2PDD genes (top) compared to GS (p-value two-tail Fisher’s Exact Test = 0.005); with no significant difference between DDD and CRC (p-value = 0.17) and CRC and GS (p-value = 0.16). There is no significant difference for the proportion of unique missense variants with CADD > 30 in the CRC and GS cohorts in G2PCancer genes (bottom, p-value = 1.0)CC BY · PubMed Central
Fig. 3 Sensitivity and precision of VEP-G2P Analysis GQ genotype quality, MAF minor allele frequency, alt:ref the ratio of alternate to reference alleles. TP true positive, FP false positive, TN true negative, FN false negative. Sensitivity = TP/(TP + FN). Precision = TP / (TP + FP). a Evaluation of G2P accuracy for likely causative variants in 94 genes achieving genome-wide significance (GWS) for de novo mutations in the DDD study. b G2P accuracy against the set of variants previously identified by DDD in the first 1133 samples, excluding de novo mutations. c ROC curves for VEP-G2PDD performance on 1700 DDD probands with de novo mutations (DNM) identified in the 484 monoallelic genes. The points on the curves represent varying MAF cut-offs: not seen in any control databases (bottom left), MAF < 1:100000, MAF < 1:50000, MAF < 1:25000, MAF < 1:10000 (top right). The region in the top left corner of the ROC space graph has been expanded to scale using the regions bounded by the dashed line rectangles. d The effect of consequence type and MAF on precision and recall (PR curves) of VEP-G2PDD using the same data analysed for the ROC space in c. The highest precision [0.812, 0.863] is achieved for LOF variants but with the lowest recall [0.425, 0.437]. The highest recall is achieved for variants of all consequence types [0.897, 0.942] at the cost of decreased precision [0.334, 0.476]. Analysing only missense variants with CADD≥ 30 or CADD ≥ 20 leads to improvements in precision at the cost of decreasing recall
Fig. 3 Sensitivity and precision of VEP-G2P Analysis GQ genotype quality, MAF minor allele frequency, alt:ref the ratio of alternate to reference alleles. TP true positive, FP false positive, TN true negative, FN false negative. Sensitivity = TP/(TP + FN). Precision = TP / (TP + FP). a Evaluation of G2P accuracy for likely causative variants in 94 genes achieving genome-wide significance (GWS) for de novo mutations in the DDD study. b G2P accuracy against the set of variants previously identified by DDD in the first 1133 samples, excluding de novo mutations. c ROC curves for VEP-G2PDD performance on 1700 DDD probands with de novo mutations (DNM) identified in the 484 monoallelic genes. The points on the curves represent varying MAF cut-offs: not seen in any control databases (bottom left), MAF < 1:100000, MAF < 1:50000, MAF < 1:25000, MAF < 1:10000 (top right). The region in the top left corner of the ROC space graph has been expanded to scale using the regions bounded by the dashed line rectangles. d The effect of consequence type and MAF on precision and recall (PR curves) of VEP-G2PDD using the same data analysed for the ROC space in c. The highest precision [0.812, 0.863] is achieved for LOF variants but with the lowest recall [0.425, 0.437]. The highest recall is achieved for variants of all consequence types [0.897, 0.942] at the cost of decreased precision [0.334, 0.476]. Analysing only missense variants with CADD≥ 30 or CADD ≥ 20 leads to improvements in precision at the cost of decreasing recallCC BY · PubMed Central
Fig. 4 Comparison of VEP-G2P to existing tools. a Comparison for 100 random DDD samples with dominant de novo sample (left panel) and 100 random DDD recessive samples (right panel). b Comparison for 100 unaffected Generation Scotland (GS) samples. Each dot represents the rank of the causative gene in the output of the tools, where rank of 1 indicates the causative gene is at the top of the list reported by the tool; boxplots show the median (centre line), the first and third quartiles (box bounds), whiskers represent 1.5∗ interquartile range from the first/third quartiles. F1 = 2∗((precision∗recall)/(precision + recall))
Fig. 4 Comparison of VEP-G2P to existing tools. a Comparison for 100 random DDD samples with dominant de novo sample (left panel) and 100 random DDD recessive samples (right panel). b Comparison for 100 unaffected Generation Scotland (GS) samples. Each dot represents the rank of the causative gene in the output of the tools, where rank of 1 indicates the causative gene is at the top of the list reported by the tool; boxplots show the median (centre line), the first and third quartiles (box bounds), whiskers represent 1.5∗ interquartile range from the first/third quartiles. F1 = 2∗((precision∗recall)/(precision + recall))CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 31 · Cited by 151

Metadata

Authors
Thormann, A., Halachev, M., McLaren, W., Moore, D. J., Svinti, V., Campbell, A., Kerr, S. M., Tischkowitz, M., Hunt, S. E., Dunlop, M. G., Hurles, M. E., Wright, C. F., Firth, H. V., Cunningham, F., & FitzPatrick, D. R.
Affiliations
  • European Bioinformatics Institute (GB)
  • Western General Hospital (GB)
  • Institute of Genetics and Cancer (GB)
  • Addenbrooke's Hospital (GB)
  • Wellcome Sanger Institute (GB)
  • University of Exeter (GB)
Corresponding author
  • Cunningham, Fiona
  • FitzPatrick, David R.
Venue
Nature Communications
Published
2019-05-30
Volume
10
Issue
1
Pages
2373-2373
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2947628999
Cited by
151
References
31
Citations by year
2026: 18 · 2025: 30 · 2024: 34 · 2023: 18 · 2022: 29 · 2021: 12 · 2020: 5 · 2019: 4
FWCI
7.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Wellcome Trust (HICF-1009-003, WT095908, GEN/284/12, 104036/Z/14/Z, UK10K, 200990/A/16/Z, WT 098051, WT108749, 10/H0305/83, WT200990/Z/16/Z, 200990, 104036, /Z/15/Z, WT108749/Z/15/Z, WT091310, 200990/Z/16/Z)
  • Scottish Government (CZD/16/6)
  • European Molecular Biology Laboratory
  • Cancer Research UK (18927, 12076)
  • National Institute for Health and Care Research (10/H0305/83, HICF-1009-003, WT098051)
  • Scottish Funding Council (HR03006)
  • European Commission (HICF-1009-003, HORIZON2020, 634143)
  • University of Edinburgh
  • Chief Scientist Office, Scottish Government Health and Social Care Directorate (HR03006, CZD/16/6)
  • Medical Research Council (104036/Z/14/Z, MC_UU_00007/3, WT098051, MC_UU_00007/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
g2p, genetic variants, phenotypic matching, developmental disorders, de novo mutations, exome sequencing, genotype-phenotype correlation
MeSH terms
Whole Genome Sequencing, Exome Sequencing, Alleles, Developmental Disabilities, Genetic Testing, Genotype, Humans, Mutation, Phenotype, Genome, Human, Sequence Analysis, DNA, Molecular Diagnostic Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP. https://app.cochat.ai/papers/10.1038/s41467-019-10016-3
The paper
Thormann, A., Halachev, M., McLaren, W., Moore, D. J., Svinti, V., Campbell, A., Kerr, S. M., Tischkowitz, M., Hunt, S. E., Dunlop, M. G., Hurles, M. E., Wright, C. F., Firth, H. V., Cunningham, F., & FitzPatrick, D. R. (2019). Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP. Nature Communications. https://doi.org/10.1038/s41467-019-10016-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.